Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2019

View Archived Issues

Rightsizing brain activity increases lifespan, but REST is not all good

Convertible CARs to the reservoir rescue?

Cirrhosis to liver cancer progression still mysterious

Encouraging phase II results reported for VPX-638

MPST a potential new biomarker in hepatocellular carcinoma

New compounds block Tat binding to human DAT for HAND treatment

SOX9 antagonist Z-02 may improve spinal cord injury

Telix and AusHealth sign agreement for APOMAB molecularly targeted radiation platform

Cyclerion Therapeutics presents topline data from two phase II studies of praliciguat

Topline results presented from phase III CMS-001 study of amifampridine phosphate

(R)-[18F]MH.MZ as a novel PET tracer for the detection of 5-HT2A receptors in the human brain

INTH-454: A small molecule modulator of the p300/CBP interactome for cancer

Preclinical evaluation of highly potent caspase-cleavable docetaxel prodrug, MPD-03

Cyclin-dependant kinase 7 inhibitors discovered by Lead Discovery Center and Qurient

Bayer Pharma describes new kallikrein B inhibitors

Shandong Luoxin Pharmacy Group and Luoxin Pharmaceutical (Shanghai) patent TLR7 agonists

First patient dosed in phase II study of novel hepcidin mimetic PTG-300

FDA approves Vumerity for the treatment of multiple sclerosis

GlaxoSmithKline Biologicals presents new Toll-like receptor 7/8 agonists

New JAK-2 inhibitors identified at East China University of Science and Technology

ACADIA Pharmaceuticals initiates phase III LAVENDER study of trofinetide in Rett syndrome

First biologic treatment approved for children with lupus in Europe

Millennium Pharmaceuticals initiates phase I/II study of TAK-981 plus rituximab in NHL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...